New Study to Explore Link Between Hypertension Treatment and Development of Heart Failure

Researchers will Study How Drug Used to Lower Blood Pressure can Change Fibroblasts to Provide Long-Lasting Protection for the Heart

Alexandra Garvin, PhD, Dana Floyd, and Taben Hale, PhD, in the Hale Laboratory  (Image: University of Arizona)

Alexandra Garvin, PhD, Dana Floyd, and Taben Hale, PhD, in the Hale Laboratory (Image: University of Arizona)

Researchers at the University of Arizona College of Medicine – Phoenix have received a grant to study how medications used to treat hypertension may provide insight into novel treatments to produce long-lasting protection against heart disease.

According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. Heart failure affects 6.2 million Americans.

Taben Hale, PhD, is the director of the Hale Laboratory at the UArizona College of Medicine – Phoenix. She will lead the study, “Targeting Resident Cardiac Fibroblast Subpopulations for Protection Against Fibrosis,” with R01 grant funding from the National Institutes of Health (NIH).

Hypertension, also known as high blood pressure, is a major risk factor for development of heart failure.

Hypertension stimulates activation of cardiac fibroblasts (CFs) — cells which play a primary role in regulating the production of the extracellular matrix (ECM) — a large network of proteins that helps cells attach to and communicate with each other.

Prolonged activation of CFs due to hypertension stimulates production of growth factors and signaling molecules in these cells, resulting in excessive ECM production. This leads to the development of fibrosis and impairs the heart’s ability to effectively pump blood to the rest of the body.

Potential Long-term Protection Against Fibrosis

Fibrosis is a common end-stage characterization of nearly every type of heart disease. Although there are no approved treatments for cardiac fibrosis, angiotensin-converting enzyme inhibition (ACE inhibitor) medications limit CF activation.

Earlier research led by Hale showed the benefits of ACE inhibitors on CFs persisted even after stopping treatment. In hearts treated with ACE inhibitors, characteristics of the CFs rendered them resistant to the remodeling that leads to fibrosis. After the treatment was stopped, the CFs retained the memory of the drug treatment. The findings show it is possible to provide long-lasting protection for the heart.
The new study will reveal the mechanisms by which CFs can be shifted to a lower activation state. By limiting CFs’ activation, researchers hope to identify methods to protect against future fibrosis. Researchers seek to determine how changes in the regulation of specific CF genes create a relatively stable phenotype that is less prone to activation.

Researchers hope the new study may contribute to the development of medications that target cardiac fibroblasts to prevent the cardiac remodeling which leads to heart failure.

About the College
Founded in 2007, the University of Arizona College of Medicine – Phoenix inspires and trains exemplary physicians, scientists and leaders to optimize health and health care in Arizona and beyond. By cultivating collaborative research locally and globally, the college accelerates discovery in a number of critical areas — including cancer, stroke, traumatic brain injury and cardiovascular disease. Championed as a student-centric campus, the college has graduated 593 physicians, all of whom received exceptional training from nine clinical partners and more than 2,400 diverse faculty members. As the anchor to the Phoenix Biomedical Campus, which is projected to have an economic impact of $3.1 billion by 2025, the college prides itself on engaging with the community, fostering education, inclusion, access and advocacy.


By Beth Smith, University of Arizona
February 11, 2022

Posted in AZBio News.